Stockreport

X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF Mavorixafor selected for LLS’s Therapy Acceleration Program® (TAP) CAMBRIDGE, Mass. & RYE BROOK, N.Y.--(BUSINESS WIRE)-- X4 Pharmaceuticals, I [Read more]